62 results
8-K
EX-99.2
ME
23andMe Holding Co - Ordinary Shares
8 Jan 24
Regulation FD Disclosure
7:45am
to address unmet medical needs Patients SPEED Antibody and protein engineering Pleiotropy informs clinical development and safety POWER Largest human … that would point to safety issues Amgen clinical trials of anti-TSLP mAb as eczema target failed. We do not observe a statistically significant genetic
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
8 Jan 24
Regulation FD Disclosure
7:45am
with great PK/PD, safety, and on-target AEs in with monotherapy Ph2a monotherapy basket (including neuroendocrine and ovarian) currently enrolling Ph2a data … Processes that Bear Out in the Clinic Rasco, D, et al., 2023, SITC Annual Meeting #619 Geno-Phenotypic Data Translates to Safety and Efficacy Signals
8-K
9ipw4qtruk05n2l43caj
6 Nov 23
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
8:15am
8-K
EX-99.1
s9py5
6 Nov 23
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
8:15am
S-8
EX-99.1
ksvm3f6g4
15 Sep 23
Registration of securities for employees
4:06pm
DEFR14A
po0c6yx4j
4 Aug 23
Revised proxy
4:05pm
DEFR14A
jpvt td65w
26 Jul 23
Revised proxy
9:14pm
8-K
EX-99.1
6lgu6f2dm7 uy3b
25 May 23
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
4:08pm
8-K
EX-99.1
91vt kxs5gtls73
17 Apr 23
Regulation FD Disclosure
4:10pm
8-K
EX-99.1
084e bzc4ehh
14 Apr 23
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
4:08pm
8-K
EX-3.1
d0tq yjzt4
9 Dec 22
Departure of Directors or Certain Officers
8:05am
8-K
EX-99.1
84yg3uinxwumen73a
9 Nov 22
Investor Presentation November 2022
7:30am
424B3
w6scxguo mn4m
7 Nov 22
Prospectus supplement
4:33pm